SANTA CLARA, Calif., Nov. 29, 2011 /PRNewswire/ -- OmniVision Technologies, Inc. (NASDAQ: OVTI), a leading developer of advanced digital imaging solutions, today announced that its ultra-compact, high-performance OV6930 CMOS image sensor performed exceptionally well in a recent 448-patient clinical study on Avantis Medical Systems' Third Eye Retroscope. The study, published in the March issue of Gastrointestinal Endoscopy, demonstrates that the Third Eye Retroscope can increase the accuracy in diagnosing adenomas, or pre-cancerous polyps, by 23.2 percent when used in conjunction with a traditional colonoscope.(1)
The Third Eye Retroscope is an FDA-cleared, disposable, catheter-based camera for use with a standard colonoscope that provides a continuous backward-looking view while the colonoscope provides the usual forward view. In 2010, Avantis received a Medicare and Medicaid reimbursement code for the Third Eye Retroscope. The companies believe that this recognition by Medicare and Medicaid, combined with the favorable results from this recent clinical study, may significantly accelerate the adoption rate by healthcare providers in the United States.
"The OV6930's excellent low-light sensitivity and image quality enabled the Third Eye to perform extraordinarily well in the clinical study, drastically improving colonoscopy accuracy," said Matthew Whitcombe, senior marketing manager at OmniVision. "Moreover, by providing this superior performance in a form factor with an exceedingly small footprint, the OV6930 allows for ultra-compact camera designs, making these medical procedures minimally invasive for the patient."
"With currently more than 150,000 cases of colorectal cancer reported annually in the U.S., and more than 400,000 in Europe, it is the second-leading cause of cancer-related deaths in the U.S. and Europe," said Doug Gielow, vice president of sales and marketing at Avantis. "However, using today's advanced imaging technologies, it can be highly preventable through early detection. Now that this product is Medicare approved, we hope to see greater adoption of this technology by healthcare providers, who can now submit claims for reimbursement. We're extremely excited to watch the disposable medical imaging market grow as physicians and patients continue to experience the added benefit of our medical imaging solutions."
The OV6930 is a CMOS image sensor designed specifically for use in medical devices. With a packaged footprint of only 1.8 x 1.8 mm, the OV6930 is an ideal solution for endoscopic applications that require a small profile, including bronchoscopy, colonoscopy, gastroscopy, OB-GYN and urology. It combines ultra-low power consumption with OmniVision's best-in-class OmniPixel3-HS™ technology, enabling low-light performance of 3300 mV/lux-sec. Its 1/10-inch array is capable of operating up to 30 frames per second (FPS) in 400 x 400 HVGA or 60 FPS in 400 x 200 resolution, providing RAW serial output. The low-voltage OV6930 allows cabling up to 14 feet, and is now shipping in volume to multiple medical device customers.
OmniVision Technologies (NASDAQ: OVTI) is a leading developer of advanced digital imaging solutions. Its award-winning CMOS imaging technology enables superior image quality in many of today's consumer and commercial applications, including mobile phones, notebooks, tablets and webcams, digital still and video cameras, security and surveillance, entertainment devices, automotive and medical imaging systems. Find out more at www.ovt.com.
Certain statements in this press release, including statements regarding the expected benefits, performance, capabilities, and potential market appeal of the OV6930 are forward-looking statements that are subject to risks and uncertainties. These risks and uncertainties, which could cause the forward-looking statements and OmniVision's results to differ materially, include, without limitation: potential errors, design flaws or other problems with OV6930, customer acceptance, demand, and other risks detailed from time to time in OmniVision's Securities and Exchange Commission filings and reports, including, but not limited to, OmniVision's annual report filed on Form 10-K and quarterly reports filed on Form 10-Q. OmniVision expressly disclaims any obligation to update information contained in any forward-looking statement.
OmniVision®, the OmniVision logo and OmniPixel® are registered trademarks of OmniVision Technologies, Inc. OmniPixel3™ is a trademark of OmniVision Technologies, Inc.
(1) Leufkens AM, DeMarco DC, Siersema PD, et al. Effect of a Retrograde-Viewing Device on Adenoma Detection Rate during Colonoscopy: The "TERRACE" Study. Gastrointest Endosc 2011;73:480-9.
SOURCE OmniVision Technologies, Inc.